FDA, NIH and Industry Publish Framework for Biomarker Qualification

Clinical Trials Advisor
A A
Officials from the FDA and the National Institutes of Health, in cooperation with public, private and industry stakeholders, published a framework for defining the levels of evidence needed to support the regulatory qualification of biomarkers for drug development.

To View This Article:

Login

Subscribe To Clinical Trials Advisor